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Pleiotrophin (PTN) is a multifunctional, cationic, glycosaminoglycan-binding cytokine and growth factor involved in
numerous physiological and pathological processes, including
tissue repair and inflammation-related diseases. PTN has been
shown to promote leukocyte responses by inducing their migration and expression of inflammatory cytokines. However, the
mechanisms through which PTN mediates these responses
remain unclear. Here, we identified the integrin Mac-1 (␣M␤2,
CD11b/CD18) as the receptor mediating macrophage adhesion
and migration to PTN. We also found that expression of Mac-1
on the surface of human embryonic kidney (HEK) 293 cells
induced their adhesion and migration to PTN. Accordingly,
PTN promoted Mac-1– dependent cell spreading and initiated
intracellular signaling manifested in phosphorylation of Erk1/2.
While binding to PTN, Mac-1 on Mac-1– expressing HEK293
cells appears to cooperate with cell-surface proteoglycans
because both anti-Mac-1 function-blocking mAb and heparin
were required to block adhesion. Moreover, biolayer interferometry and NMR indicated a direct interaction between the ␣MI
domain, the major ligand-binding region of Mac-1, and PTN.
Using peptide libraries, we found that in PTN the ␣MI domain
bound sequences enriched in basic and hydrophobic residues,
indicating that PTN conforms to the general principle of ligandrecognition specificity of the ␣MI domain toward cationic proteins/peptides. Finally, using recombinant PTN-derived fragments, we show that PTN contains two distinct Mac-1– binding
sites in each of its constitutive domains. Collectively, these
results identify PTN as a ligand for the integrin Mac-1 on the
surface of leukocytes and suggest that this interaction may play
a role in inflammatory responses.

Pleiotrophin (PTN)3 is a glycosaminoglycan-binding cytokine and growth factor with potent mitogenic and angiogenic
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activities. Together with the related protein midkine, it forms a
unique family of cytokines that are normally expressed during
embryogenesis and neonatal development but are also produced by injured tissues during repair and regeneration (1, 2).
PTN has also been identified as crucial in the maintenance of
hematopoietic stem cells (3, 4). Moreover, PTN levels have
been shown to be highly elevated in a large number of cancer
cell lines as well as being correlated with their metastatic abilities (5–13). Several studies have also associated PTN with
inflammation and leukocyte recruitment (13, 14). There are
now efforts both to develop PTN inhibitors to treat cancer and
to use PTN itself for prevention of tissue injury during ischemia
(15–18). Several proteins have been proposed as receptors of
PTN. The most studied among these include the heparan sulfate proteoglycan (HSPG) N-syndecan and the chondroitin sulfate proteoglycan receptor-type protein tyrosine phosphatase 
(19 –21). Several non-proteoglycan receptors are also known to
bind PTN, including nucleolin (22, 23) and the integrin ␣V␤3
(24).
Structurally, PTN is made up of two thrombospondin type-1
repeat (TSR) domains flanked by unstructured termini, both of
which are highly basic (25, 26). The TSR domains also contain a
number of basic amino acid clusters with two clusters in the
C-terminal TSR domain having the highest affinity for glycosaminoglycans (25, 27). It is thought that the basic nature of PTN
is crucial to its ability to interact with receptors and initiate
signaling.
Although the role of PTN in mitogenesis and angiogenesis
has been extensively researched, its function in inflammation
has not been widely explored. Given the fact that injured tissues
express PTN, it is likely that leukocytes are exposed to it at sites
of inflammation. Indeed, some studies have suggested that PTN
plays a role in recruitment of leukocytes during inflammation
(13, 14). However, the identity of the PTN receptor(s) on leukocytes that mediate this response and the role of PTN signaling in these cells remain unknown. We hypothesized that integrin ␣M␤2 (Mac-1, CD11b/CD18, CR3) can serve as a receptor
for PTN. This hypothesis was based on our recent finding that
Mac-1 binds cationic proteins, many of which, similar to PTN,
interact with heparin (28 –30).
protein; ECM, extracellular matrix; BLI, biolayer interferometry; HSQC, heteronuclear single quantum coherence; NTD, N-terminal TSR domain; CTD,
C-terminal TSR domain; CS, chondroitin sulfate; CSPG, chondroitin sulfate
proteoglycan; MK, midkine; PVP, polyvinylpyrrolidone.
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PTN is a ligand for integrin Mac-1
Mac-1 is an adhesion receptor expressed on the surface of
myeloid cells such as monocyte/macrophages and neutrophils.
As an adhesion receptor, Mac-1 is crucial to numerous leukocyte responses, including migration, phagocytosis, degranulation, adherence to microorganisms, and others (31, 32). Among
integrins, which are in general notorious for their capacity to
recognize multiple ligands, Mac-1 is its most promiscuous
member. In contrast to many other integrins that recognize the
RGD motif, Mac-1 does not bind this sequence. Instead, as we
have recently revealed, Mac-1 has preferences for sequences
enriched in basic and hydrophobic amino acid residues (29, 30,
33, 34). The identification of Mac-1 recognition motifs has led
to the prediction that other cationic proteins and peptides
released from leukocytes and other cells during tissue injury
can serve as Mac-1 ligands (29). Most of Mac-1’s ligand binding
and thus its broad ligand binding specificity can be attributed to
the ␣MI domain, a region of ⬃200 amino acid residues inserted
into the ␣M subunit, inasmuch as its removal in Mac-1 eliminates ⬃85% of ligand binding (35).
In this study, we present biochemical and cell biology evidence that PTN is a ligand for Mac-1. Using various Mac-1–
expressing cells, we demonstrate that Mac-1 supports adhesion
to PTN, promotes spreading, and induces activation of the
MAP kinase Erk1/2. Furthermore, PTN induces a potent
migratory response in Mac-1– expressing human embryonic
kidney 293 (Mac-1 HEK293) cells and in isolated murine
macrophages. Direct interaction between PTN and the ␣MI
domain, the major ligand-binding region of Mac-1, has been
shown using biolayer interferometry analyses and confirmed by
solution NMR spectroscopy. Finally, using peptide array analysis, we identified the putative ␣MI domain-binding sites in
both TSR domains of PTN and validated their importance in
cell adhesion and signaling assays with individual recombinant
PTN fragments.

Results
Mac-1 is involved in adhesion of Mac-1– expressing cells to
PTN
To assess whether PTN can bind Mac-1, we initially examined the ability of Mac-1 HEK293 to adhere to immobilized
PTN. As shown in Fig. 1A, Mac-1 HEK293 cells adhered to
immobilized PTN in a concentration-dependent manner with
saturable adhesion achieved with a PTN coating concentration
of ⬃100 nM. Wild-type HEK293 cells also strongly adhered to
PTN. However, the presence of Mac-1 significantly augmented
adhesion (Fig. 1A). Because PTN has high affinity for glycosaminoglycans and HSPG N-syndecan binds PTN, we examined
the possibility that HSPGs on wild-type HEK293 cells mediate
adhesion to PTN. Preincubation of cells with heparin (1 g/ml)
almost completely eliminated adhesion (Fig. 1B), indicating
that on the surface of these cells HSPGs are entirely responsible
for PTN binding. However, adhesion of Mac-1 HEK293 cells
was reduced by only ⬃60%, suggesting that Mac-1 on these cells
may be involved in binding PTN. To investigate this possibility,
Mac-1 HEK293 cells were treated with the function-blocking
mAb 44a (directed against the ␣MI domain of Mac-1). Although
adhesion tended to decrease, it was not significantly altered

with the maximal blocking effect (19 ⫾ 10%) observed at 10
g/ml of mAb. Likewise, although heparin inhibited adhesion
in a dose-dependent manner, the maximal blocking effect
attained did not exceed 59 ⫾ 6%. However, when Mac-1
HEK293 cells were treated with both mAb 44a and heparin, cell
adhesion was inhibited by ⬎95%. These results suggest both
HSPG and Mac-1 can act as receptors for PTN.
Consistent with the role of Mac-1 in adhesion to PTN, Mac-1
HEK293 cells spread with the formation of actin filaments as
detected by staining with Alexa Fluor 546-conjugated phalloidin (Fig. 1C, upper panels). By contrast, spreading of wild-type
HEK293 cells was visibly less even after 24 h (Fig. 1C, bottom
panels). Quantification of cell spreading confirmed this observation (Fig. 1D).
To investigate the relevance of PTN–Mac-1 interaction in
immune cells, we performed adhesion assays using IC-21 cells,
a murine macrophage cell line naturally expressing Mac-1. As
shown in Fig. 1E, IC-21 cells adhered to immobilized PTN, and
⬃65% of adhesion was inhibited by mAb M1/70 against the
murine ␣M integrin subunit. This is in contrast to Mac-1
HEK293 cells whose adhesion to PTN was reduced modestly by
mAb 44a (Fig. 1B). Moreover, heparin, which greatly decreased
adhesion of Mac-1 HEK293 cells to PTN, had little effect on
adhesion of IC-21, suggesting that Mac-1 on the surface of
IC-21 cells largely contributes to the interaction with PTN.
Together, these results identify PTN as an adhesive ligand for
Mac-1 and suggest that on the surface of different cells both
Mac-1 and HSPGs are involved in PTN adhesion, albeit to a
different extent.
PTN bound to extracellular matrix (ECM) proteoglycans
supports adhesion of Mac-1 HEK293 cells
Because PTN is secreted from cells and deposited into the
ECM, we explored whether PTN bound to the ECM components is capable of supporting adhesion. Because Mac-1 is
known to interact with a number of ECM proteins, including
fibronectin, vitronectin, collagens, Cyr61, and others (36), a
heterogeneous mixture of these molecules such as those found
in Matrigel was not suitable as a substrate for investigations of
PTN–Mac-1 interactions. PTN is only known to bind proteoglycans; therefore, the most relevant form of PTN encountered by immune cells in vivo is likely to be PTN anchored to
ECM proteoglycans. To simulate such an environment, we
studied cell adhesion to PTN prebound to aggrecan, a common
proteoglycan found in the ECM. Fig. 2 shows that at two concentrations of PTN tested both Mac-1 HEK293 and wild-type
HEK293 (HEK293) cells adhered to aggrecan-bound PTN with
Mac-1 HEK293 cells adhering at a significantly higher level
than HEK293 cells (p ⬍ 0.001). Neither type of cells had affinity
for aggrecan itself. Notably, binding of PTN to aggrecan did not
reduce cell adhesion, indicating that PTN in its aggrecanbound form remains an efficient Mac-1 ligand.
PTN induces migration of Mac-1– expressing cells
PTN is known to induce cell migration, and in some
instances, this effect has been shown to be integrin-dependent
(24, 37). Therefore, we investigated whether Mac-1 can support
PTN-induced migration. In particular, using a Transwell sysJ. Biol. Chem. (2017) 292(46) 18848 –18861
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Figure 1. PTN supports adhesion and spreading of Mac-1– expressing HEK293 cells and IC-21 macrophages. A, aliquots (100 l; 5 ⫻ 104/ml) of Mac-1
HEK293 and HEK293 cells labeled with calcein were added to microtiter wells coated with different concentrations of PTN and postcoated with 1% PVP. After
30 min at 37 °C, nonadherent cells were removed by washing, and fluorescence of adherent cells was measured in a fluorescence plate reader. Data shown are
means ⫾ S.E. from three separate experiments with triplicate measurements. *, p ⱕ 0.05. Statistically insignificant differences are not labeled. B, Mac-1 HEK293
cells and HEK293 cells were preincubated with anti-␣M mAb 44a (5 g/ml), heparin (1 g/ml), or a mixture of both for 20 min and added to wells coated with
100 nM PTN. Adhesion in the absence of Mac-1 inhibitors and heparin was assigned a value of 100%. Data shown are means ⫾ S.E. Error bars represent S. E. from
three separate experiments with triplicate measurements. ***, p ⱕ 0.001 compared with control adhesion in the absence of inhibitors; n/s, not significant. C,
Mac-1 HEK293 (upper panel) and HEK293 cells (lower panel) were plated on glass slides coated with 100 nM PTN and allowed to adhere for different durations
at 37 °C. Nonadherent cells were removed, and adherent cells were fixed with 2% paraformaldehyde and permeabilized with 0.1% Triton X-100 in PBS followed
by staining with Alexa Fluor 546 phalloidin (actin) and DAPI (DNA). The cells were imaged with a Leica SP5 laser-scanning confocal microscope with a 63⫻/1.4
objective. D, the diameter of 20 –50 Mac-1 HEK293 and HEK293 cells was calculated for each time point from images captured with a 20⫻/0.50 objective. Data
shown are means ⫾ S.E. from five random images for each time point from one to four experiments. Error bars represent S. E. *, p ⱕ 0.05; ***, p ⱕ 0.001. E, IC-21
macrophages were preincubated with anti-mouse ␣M mAb M1/70 (10 g/ml), heparin (1 g/ml), or a mixture of both and added to wells coated with 100 nM
PTN. Data shown are means ⫾ S.E. from three separate experiments with six measurements. Error bars represent S. E. ***, p ⱕ 0.001.

tem, we compared the ability of wild-type and Mac-1 HEK293
cells to migrate toward PTN. Previous studies reported that
these cell lines are a useful system for assessing the role of
Mac-1 in migration (38). PTN induced a potent migratory
response (Fig. 3, A and B). In contrast, wild-type HEK293
migrated only slightly. Direct evidence that migration of Mac-1
HEK293 cells was dependent on Mac-1 was obtained in the
experiments in which anti-Mac-1 mAb 44a was tested.
Although mAb 44a eliminated cell migration, an IgG1 isotype
control for this mAb had no significant effect (Fig. 3B). Heparin
(1 g/ml) also inhibited migration to a modest but significant
degree.

18850 J. Biol. Chem. (2017) 292(46) 18848 –18861

In a separate set of experiments, we tested whether PTN can
induce migration of mouse macrophages isolated from the peritoneum of wild-type and Mac-1– deficient mice. Macrophages
were purified from a total population of peritoneal cells, and
their migration was examined in a Transwell system. As shown
in Fig. 3, C and D, PTN induced a strong migratory response in
wild-type macrophages. PTN also induced migration of Mac1– deficient macrophages. However, compared with wildtype cells, migration of Mac-1– deficient macrophages was
significantly impaired (by 76 ⫾ 21%). These results indicate
that Mac-1 is a crucial mediator of PTN-induced cell migration. Furthermore, because macrophages lacking Mac-1 can
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Figure 2. Effect of aggrecan on PTN-mediated adhesion of Mac-1–
expressing HEK293 cells. Aggrecan (10 g/ml) was used to coat the microtiter wells overnight before addition of PTN (150 and 900 nM). Aliquots (100 l;
5 ⫻ 104/ml) of calcein-labeled Mac-1 HEK293 and wild-type HEK293 cells
were added to microtiter wells. After 30 min at 37 °C, nonadherent cells were
removed by washing, and fluorescence of adherent cells was measured in a
fluorescence plate reader. Data shown are means ⫾ S.E. from two separate
experiments with six measurements. Error bars represent S. E. **, p ⱕ 0.01; ***,
p ⱕ 0.001.

migrate, albeit at a significantly reduced rate, other integrins
(most likely ␣V␤3) may contribute to migration.
PTN induces activation of MAP kinase (MAPK) Erk1/2
The interaction of integrins with ligands is known to induce
activation of MAP kinases. To determine whether PTN activates MAPKs via binding to Mac-1, adherent Mac-1 HEK293
cells were treated with different concentrations of PTN, and
phosphorylation of Erk1/2 was examined. A PTN concentration of 0.7 M induced a significant increase in phosphorylation
of Erk1/2, and this response was blocked by mAb 44a and heparin (Fig. 4, A and B). The simultaneous use of two reagents
increased the inhibitory effect; however, the cumulative effect
did not reach a statistical significance. Treatment of control
HEK293 cells with PTN did not induce phosphorylation of
Erk1/2 (Fig. 4A). These data suggest that in this system initiation of intracellular signaling by PTN requires both Mac-1 and
HSPGs.
Biochemical analyses of the interaction between PTN and
␣MI domain
To further characterize the Mac-1–PTN interactions and
determine domains of Mac-1 responsible for PTN binding, we
analyzed the binding parameters of the interaction between the
␣MI domain and PTN. We focused on the ␣MI domain because
this domain is the major ligand-binding region in Mac-1, and
previous studies have shown that several basic proteins and
peptides interact with it (28 –30, 34, 39). To measure the affinity
of the ␣MI domain–PTN interaction, we used biolayer interferometry (BLI) in which PTN was coupled to the matrix coating
the biosensor via lysines. The interaction between PTN with
both active and nonactive forms of the ␣MI domain was measured in 20 mM HEPES buffer containing 150 mM NaCl, 1 mM
MgCl2, and 0.05% Tween 20, pH 7.5. When PTN was allowed to
interact with various concentrations of soluble active ␣MI

domain, a dose-dependent binding was observed (Fig. 5, A and
B). The dissociation rate constant (Kd) value determined from
the maximal responses achieved in the equilibrium portion of
the BLI sensorgrams was 1.2 ⫾ 0.2 M. The interaction of PTN
with nonactive ␣MI domain was also detected (Fig. 5C); however, binding was lower than that of the active form, which
precluded an accurate assessment of the Kd value. In contrast to
the ␣MI domains, the active form of the I domain of integrin
␣L␤2, which has narrow ligand specificity and binds only intercellular adhesion molecule and JAM-1 molecules, did not bind
PTN (Fig. 5C). To assess how divalent cations might affect the
interaction of PTN with ␣MI domain, the binding of active ␣MI
domain was measured in the presence of 5 mM EDTA. As
shown in Fig. 5C, EDTA only modestly decreased binding of
active ␣MI domain. The latter result indicates that the ␣MI
domain binding to PTN is not dependent on the presence of
Mg2⫹.
Because recognition by the ␣MI domain of many of its ligands
depends on basic amino acids, we sought to determine whether
immobilization of PTN onto the BLI sensor using lysine side
chains may potentially reduce PTN’s binding to ␣MI domain.
Therefore, we repeated the experiments by randomly biotinylating glutamate and aspartate side chains of PTN and
attaching the biotinylated PTN to streptavidin-coated sensors. As determined from the sensorgrams shown in Fig. 5D,
the alternative mode of immobilization did not change considerably the binding affinity of the two proteins (Kd ⫽ 3.9 ⫾
0.1 M).
We also examined the interaction of PTN with the active ␣MI
domain using solution NMR. Fig. 6A shows the 1H-15N HSQC
spectrum of PTN in the presence and absence of 1 molar eq of
active ␣MI domain. Addition of the ␣MI domain decreased the
signal intensities of residues in the TSR domains of PTN by
⬃40%, whereas PTN residues in the unstructured N and C termini were not affected by ␣MI domain (Fig. 6B). A signal intensity decrease often takes place when a small protein binds a
larger protein or if the interactions between the two is dynamic
and the kinetics of the interaction is on the intermediate
NMR time scale (40). The observation of a signal intensity
decrease therefore indicates that the TSR domains of PTN
are involved in binding ␣MI domain. Together, these data
indicate that PTN has a significant affinity for the active
form of the ␣MI domain.
Screening of the PTN-derived peptide libraries for ␣MI domain
binding
To localize the putative ␣MI domain-binding sites in PTN,
we screened the cellulose-bound peptide library representing
the complete sequence of PTN. The library, consisting of 9-mer
peptides with a 3-residue offset (Fig. 7A), was probed with 125Ilabeled recombinant ␣MI domain. The screening identified
four peptide clusters that strongly bound ␣MI domain (Fig. 7B).
These clusters correspond to the following PTN sequences:
1–15 (cluster 1; spots 1–3), 46 – 69 (cluster 2; spots 16 –21),
82–99 (cluster 3; spots 28 –31), and 106 –132 (cluster 4; spots
36 – 42). Control spots containing only ␤-Ala spacer (spots 49
and 50) were negative as were many other peptides. The ␣MI
domain-binding peptides were analyzed by a computer proJ. Biol. Chem. (2017) 292(46) 18848 –18861
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Figure 3. Migration of Mac-1– expressing cells to PTN in a Transwell system. A, Transwell inserts were coated with 67 nM PTN for 3 h at 37 °C. Mac-1 HEK293
cells (100 l at 3 ⫻ 106/ml) were added to the upper wells of the Transwell chamber, and their ability to migrate was analyzed. After 16 h at 37 °C, the cells were
labeled with calcein-AM for 30 min at 37 °C, and the cells from the upper chamber were removed by wiping with a cotton-tipped applicator. Images of the cells
on the underside of the Transwell filter were taken with a 10⫻/0.25 objective. The figure is representative of three experiments. In separate experiments, cells
were preincubated with 20 g/ml 44a mAb or IgG1 isotype control mAb or 1 g/ml heparin for 20 min before loading to the upper wells. B, quantification of
cell migration. The number of migrated cells was determined using NIH ImageJ. Migration was expressed as percentage of pixel intensity of images from at
least three random fields per well. The data shown are means and S.E. from three individual experiments. Error bars represent S. E. Migration of cells in the
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fluorescence of migrated cells per field ⫾S.E. for four random fields per well from three individual experiments. Error bars represent S. E. ***, p ⱕ 0.001.

gram designed to determine the capacity of peptides to interact
with the ␣MI domain (29). The program assigns each peptide an
energy value, which serves as a measure of probability that the
␣MI domain binds this sequence: the lower the energy, the
higher the likelihood that the sequence binds the ␣MI domain.
As previously determined, strong ␣MI domain-binding peptides derived from various Mac-1 ligands have energy values in
the range of ⫺20 to 2 kJ/mol. The analyses showed a good
relationship between the energy scores and the ␣MI-binding
activity of PTN-derived peptides revealed in peptide scans
(Fig. 7A). In agreement with previous findings (29), peptides
enriched in positively charged and hydrophobic residues had
the highest affinities for the ␣MI domain (spots 2, 16 –19, 29, 38,
and 42). For example, the stretch of overlapping peptides KQTMKTQRCKIPCNWKKQ (spots 16 –19) and peptide KTRTGSLKR (spot 29) contain several short motifs, HyB and BHy
where Hy represents any hydrophobic residue and B (basic) is
either arginine or lysine, that have been shown to be abundant
in the ␣MI domain binders (29). When mapped onto the threedimensional structure, the ␣MI domain-binding sequences
were found in both TSR domains as well as the N- and C-terminal tails (Fig. 7C). These results indicate that, in the case of
PTN, the ␣MI domain has affinity for its positively charged
regions, and thus recognition specificity toward PTN conforms
to the general principles of ligand recognition exhibited by
Mac-1 toward cationic proteins (29).

18852 J. Biol. Chem. (2017) 292(46) 18848 –18861

Individual TSR domains of PTN support Mac-1– dependent cell
adhesion and induce activation of Erk1/2
The above data from peptide library screening suggest that
PTN may contain several ␣MI domain-binding sites. These sites
have been mapped to the N- and C-terminal (NTD and CTD)
TSR domains of PTN as well as the C-terminal tail. To investigate the contribution of each domain to Mac-1 binding, we
prepared truncated PTN fragments corresponding to the NTD
(residues 1–57), CTD (residues 58 –114), and PTN-short (residues 1–114) with the C-terminal tail deleted (Fig. 8A) and
examined their ability to support cell adhesion and induce
MAPK activation (Fig. 8, B–F). The data showed that removing
the C-terminal tail of PTN did not reduce significantly the ability of PTN-short to support adhesion of Mac-1 HEK293 cells
compared with intact PTN (Figs. 8B and 1A). Furthermore, the
pattern of adhesion of HEK293 cells to PTN-short (Fig. 8B) was
similar to that of wild-type PTN (Fig. 1A). Both NTD and CTD
were also able to support adhesion (Fig. 8, C and D). However,
removing either one of the structural domains of PTN resulted
in the reduction of their adhesion-promoting activity (Fig. 8, C
and D). In particular, although a 100 nM coating concentration
of wild-type PTN was sufficient to achieve a saturable level of
adhesion, ⬃5- and ⬃10-fold higher concentrations of CTD and
NTD, respectively, were required to reach saturation. Furthermore, the maximal level of adhesion mediated by these frag-
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Figure 4. PTN-induced phosphorylation of Erk1/2 in wild-type HEK293
and Mac-1 HEK293 cells. A, adherent HEK293 or Mac-1 HEK293 cells were
treated with 0.7 M PTN in the absence and presence of mAb 44a (10 g/ml),
heparin (10 g/ml), or a combination of both. After 30 min at 37 °C, cells were
washed and lysed. The lysates were separated by 12.5% SDS-PAGE, and Western blotting was performed using mAb specific for the phosphorylated form
of Erk1/2. The mAb against total Erk1/2 was used to equalize protein loading.
A representative of three experiments is shown. The molecular weight markers are shown on the left of each set of blots. B, densitometry analysis of Erk1/2
phosphorylation for Mac-1 HEK293 cells. Erk1/2 activation data are shown as
a ratio of the intensity of the phosphorylated Erk1/2 (p-Erk1/2) band to the
total (Erk1/2) band. The phosphorylated Erk1/2-to-Erk1/2 ratio of the PTNactivated lane was set to 1.0. Data are calculated from three experiments.
Error bars represent S. E. **, p ⱕ 0.01.

ments was lower than that mediated by intact PTN. The effect
of the removal of either structural domain of PTN on proteoglycan binding was even more severe. Specifically, wild-type
HEK293 cells adhered poorly to NTD and CTD even at a concentration of 1 M (Fig. 8, C and D). To rule out the possibility
that differences in the adhesion-promoting activity of PTNderived fragments were due to their different coating efficiencies, we examined the ability of soluble fragments to inhibit
adhesion. Wild-type PTN and all fragments blocked adhesion
in a dose-dependent manner (supplemental Fig. S1). At 5 M,
wild-type PTN was the most potent inhibitor (78 ⫾ 13% inhibition of adhesion) followed by PTN-short (68 ⫾ 15%), CTD
(57 ⫾ 10%), and NTD (38 ⫾ 12%) (Fig. 8E), thus corroborating
the results of adhesion assays. Consistent with the presence of
the Mac-1– binding sites in both NTD and CTD domains,
treatment of Mac-1 HEK293 cells with each fragment resulted
in phosphorylation of Erk1/2, whereas only basal phosphorylation was detected in untreated cells (Fig. 8F and supplemental
Fig. S2).

Discussion
PTN is a 15-kDa basic heparin-binding protein that induces
proliferation, cell growth, and angiogenesis in a wide variety of
cells by interacting with specific receptors, including receptortype protein-tyrosine phosphatase (RPTP) ␤/, anaplastic lymphoma kinase, N-syndecan, and ␣V␤3 (3–5, 9, 24). PTN has also

been implicated in mediating inflammation based on its ability
to trigger in vivo migration of neutrophils and monocyte/
macrophages (13, 14). In this study, we demonstrated that PTN
induces a potent migratory response in macrophages in vitro
and identified integrin Mac-1 as the major receptor mediating
cell migration. In support of this finding, we showed that PTN
induces migration of Mac-1– expressing HEK293 cells and
wild-type mouse macrophages but not wild-type HEK293
cells or Mac-1– deficient macrophages. Mac-1 expressed on
HEK293 cells also augmented adhesion to PTN compared with
wild-type HEK293 cells and specifically promoted cell spreading. Similarly, PTN also supported adhesion of IC-21 mouse
macrophages in a Mac-1– dependent manner. In addition,
Mac-1 was essential for PTN-induced activation of Erk1/2.
Finally, we showed direct interaction between ␣MI domain, the
ligand-binding region of Mac-1, and PTN using BLI and NMR.
These observations establish PTN as a novel ligand for integrin
Mac-1 and suggest a role for this protein in the pathophysiologic functions of myeloid leukocytes, which specifically
express this receptor.
Integrin Mac-1 is a member of the ␤2 subfamily of integrin
adhesion receptors and is the major receptor on the surface of
neutrophils and monocytes/macrophages. This receptor contributes to leukocyte adhesion to and diapedesis through the
inflamed endothelium and controls leukocyte migration to sites
of inflammation. Moreover, ligand engagement by Mac-1 initiates a variety of cellular responses, including phagocytosis, neutrophil degranulation and aggregation, and expression of cytokines/chemokines and many other pro- and anti-inflammatory
molecules (31, 32, 41). Innumerable roles played by Mac-1 in
leukocyte biology arise from its multiligand binding properties.
Indeed, this receptor exhibits broad recognition specificity and
is capable of binding an extremely diverse group of protein and
nonprotein ligands. We recently showed that, within its many
ligands, Mac-1 binds not to a specific amino acid sequence but
rather has a preference for the sequence patterns consisting of a
core of positively charged residues flanked by hydrophobic residues (29). In particular, the binding motifs for Mac-1 can be
coded as HyBHy, HyHyBHy, HyBHyHy, and HyHyBHyHy.
Other amino acids can also be found, but in general, their proportion within the Mac-1– binding motifs is very small, and
negatively charged (acidic) residues are largely omitted.
Analyses of the PTN sequence by a previously developed program (29) that predicts the Mac-1– binding sites in its ligands
showed that PTN contains several potential ␣MI domain-recognition sequences, and this prediction was confirmed experimentally (Fig. 7). Screening of the peptide library spanning the
sequence of PTN demonstrated the presence of four clusters
composed of overlapping ␣MI domain-binding peptides (Fig. 7,
A and B). The ␣MI domain-binding peptides in clusters 2 and 3
correspond to the segments that form the structural NTD and
CTD of PTN. Sequences in the C-terminal part of cluster 2
correspond to the segment in the hinge region (residues
58 – 66) connecting the TSR domains (Fig. 7, A and C). In addition, the ␣MI domain-binding sequences identified within clusters 1 and 4 are present in the N- and C-terminal tails, respectively (Fig. 7C). The PTN structure shows that each PTN
domain possesses large basic surfaces formed by segments
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enriched in lysine and arginine that are brought into close proximity by PTN folding (Fig. 9) (25). Within CTD, Lys68, Lys84,
Arg86, Lys91, Arg92, and Lys107 contribute to the formation of an
extended basic surface (Fig. 9B). Within NTD, Arg35, Arg39,
and Lys49 contribute to the basic surface on one side of the
␤-sheet forming the domain (Fig. 9A). Side chains of Tyr69,
Leu90, Val103, and Ile105 in CTD form a small hydrophobic cluster in the middle of CTD (25). Furthermore, Phe63 in the hinge
segment that connects NTD and CTD has significant contacts
with side chains of residues in the hydrophobic cluster. Because
of these interactions, the bend formed in the hinge places Lys60
and Lys61 close to the basic surface in CTD (Fig. 7C). Interestingly, all of the residues forming the basic surfaces in CTD and
NTD as well as those found in the hydrophobic cluster and the
hinge were found in the ␣MI domain-binding clusters 2 and 3,
and two residues (Val103 and Lys105) are in the beginning of
cluster 4. Because basic and hydrophobic amino acid residues
were shown to be the main contributors to the interaction
between the ␣MI domain and peptides in the previously
screened libraries of Mac-1 ligands (29, 30, 34), it is possible
that the basic surfaces in CTD and NTD form the binding sites
for the ␣MI domain. The identification of the majority of the
␣MI domain-binding residues in NTD and CTD is in agreement
with the NMR data showing that many residues in these
domains were perturbed in the presence of ␣MI domain (Fig. 6).
To validate the relevance of the proposed Mac-1– binding
sites, we investigated adhesion of Mac-1– expressing HEK293
cells to truncated PTN fragments. The results showed that
immobilized NTD and CTD can independently support Mac1– dependent adhesion, and soluble NTD and CTD can inhibit
cell adhesion to intact PTN, albeit to a lower extent than soluble
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intact PTN (Fig. 8, B–E). Interestingly, removal of each NTD or
CTD reduced PTN’s affinity for cell-surface proteoglycans to a
greater extent than its affinity for Mac-1 (Fig. 8, C and D), suggesting that proteoglycans are involved but not absolutely
required for adhesion. Based on these data, it is reasonable to
propose that each of the two structural domains of PTN can
bind Mac-1 independently. Furthermore, it appears that both
domains of PTN are required for the optimal proteoglycan
binding, and thus the enhanced adhesion of Mac-1– expressing
cells to intact PTN may result from the cooperative binding of
Mac-1 and proteoglycans.
Consistent with the role of proteoglycans in Mac-1–
mediated cell adhesion, previous studies demonstrated that soluble heparin partially blocks adhesion of Mac-1– expressing
cells, including human monocytes to various ligands (28, 30,
34). Moreover, the inhibitory effect of anti-Mac-1 functionblocking reagents has been potentiated by heparin. We
observed similar effects of heparin and anti-Mac-1 functionblocking mAb 44a on adhesion of Mac-1 HEK293 cells to PTN
(Fig. 1). Heparin also partially inhibited migration of Mac-1
HEK293 cells. However, in contrast to adhesion, mAb 44a completely inhibited migration even in the absence of heparin, indicating that Mac-1 was absolutely required for migration (Fig. 3,
C and D). These findings suggest that, although HSPGs may
influence cell migration in this system, PTN engagement by
Mac-1 is indispensable for triggering intracellular signaling that
initiates migration. Heparin may exert its inhibitory effect by
binding to the heparin-binding sites in PTN or by interacting
with Mac-1. Indeed, both NTD and CTD of PTN contain sites
that bind heparin with high affinity (27, 42). Furthermore, heparin has also been shown to interact with the ␣MI domain of
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Mac-1 (43), although the binding site(s) remains uncertain.
These findings suggest that, if present, HSPGs on leukocytes
may participate in optimal adhesion and migration to PTN.
Moreover, PTN has high affinity for chondroitin sulfate (CS) A
and E with a Kd in the low nM range (27, 42). This suggests that
CS, which (similar to heparin) is covalently attached to several
core proteins, creating a variety of CSPGs on the cell surface,
can act cooperatively with Mac-1. The complex relationship
among PTN, Mac-1, and cell-surface HS/CS proteoglycans
remains poorly understood. Because PTN contains two glycosaminoglycan-binding sites in NTD and CTD and can bind the
␣MI domain through the same basic surfaces, it may potentially
bridge Mac-1 and proteoglycans, inducing their clusterization.
The additional binding site for glycosaminoglycans in the
C-terminal tail of PTN may also participate in the formation of
complexes between Mac-1 and HS/CSPG, further increasing
the complexity of multimolecular clusters. Given noticeable

differences in the affinity of PTN domains for glycosaminoglycans, it is reasonable to propose that this variability may influence the interactions of PTN with Mac-1 on leukocytes and
thus affect cell adhesion, migration, and other Mac-1– dependent leukocyte responses. Interestingly, although HSPGs on
Mac-1– expressing HEK293 cells and human monocytes (28)
cooperate with Mac-1 in PTN binding, their role in adhesion
of IC-21 mouse macrophages appears to be less important
because heparin alone does not inhibit adhesion, whereas antiMac-1 mAb produces a strong inhibitory effect (Fig. 1E). The
reason for the differential involvement of proteoglycans in PTN
recognition is unclear but may stem from differences in the
composition of glycosaminoglycans expressed on various cells.
In addition to cell-surface proteoglycans, ECM proteoglycans
may also play a role in storage and presentation of PTN to
migrating cells. In this regard, we showed that PTN bound to
aggrecan, a well-known CSPG in the ECM, supports adhesion,
suggesting that PTN deposited in the ECM remains an active
Mac-1 ligand.
Binding of several ligands to Mac-1 is controlled by the activation state of the receptor. Previous studies demonstrated that
the ␣MI domain exists in two different conformations, active
and nonactive, with the position of the C-terminal ␣7 helix
regulating its activation state (44). In contrast to such Mac-1
ligands as C3bi, recognition of which requires the active state of
the ␣MI domain (45), the nonactive form of the ␣MI domain
bound PTN, albeit to a lower extent than active ␣MI domain
(Fig. 5C). This finding suggests that the ␣MI domain binding to
PTN is not strictly activation-dependent. Furthermore, in contrast to other integrin ligands, binding of PTN to the active ␣MI
domain still occurred in the absence of Mg2⫹ or in the presence
of EDTA (Fig. 5C). Similar characteristics, i.e. the lack of dependence on the activation state of the ␣MI domain and divalent
cations, have been noted with some Mac-1 ligands, including
opioid peptide dynorphin A (30), fibrinogen peptide P2-C (39),
and cationic proteins myeloperoxidase and elastase.4 Because
all these molecules are highly positively charged and their binding to the ␣MI domain is mediated by sequences enriched in
basic residues (29), it is tempting to speculate that cationic peptides/proteins represent a unique group of Mac-1 ligands that
bind the ␣MI domain through activation- and cation-insensitive mechanisms. Further structural studies of the ␣MI domainPTN complex may help to define the mechanism of this
interaction.
Although the biological significance of leukocyte interaction
with PTN remains to be established, the expression of PTN in
different cells during regeneration after injury (2, 46) suggests
that it may play a role in inflammatory responses. In this regard,
PTN has been shown to promote neutrophil and mononocyte/
macrophage recruitment during liver regeneration and peritoneal fibrosis (13, 14). Our in vitro studies showing that Mac-1
can mediate migration of macrophages and Mac-1– expressing
HEK293 cells to PTN suggest that leukocyte migration in vivo
may also be driven by this receptor. Furthermore, the only
known PTN homolog, midkine (MK), which shares 50%
4

D. Shen, N. P. Podolnikova, V. P. Yakubenko, C. L. Ardell, A. Balabiyev, T. P.
Ugarova, and X. Wang, unpublished data.
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Figure 8. PTN fragments support adhesion, inhibit adhesion, and induce Erk1/2 activation in Mac-1– expressing HEK293 cells. A, a schematic representation of the domain structure of PTN and recombinant fragments used in the adhesion and Erk1/2 activation assays. B, aliquots (100 l; 5 ⫻ 104/ml) of
Mac-1 HEK293 and wild-type HEK293 cells labeled with calcein were added to microtiter wells coated with different concentrations of truncated PTN without
the C-terminal tail (PTN-short) and postcoated with 1% PVP. After 30 min at 37 °C, nonadherent cells were removed by washing, and fluorescence of adherent
cells was measured. Data shown are means ⫾ S.E. from three separate experiments with triplicate measurements. Error bars represent S. E. *, p ⱕ 0.05; **, p ⱕ
0.01; ***, p ⱕ 0.001. C and D, adhesion assays with immobilized NTD (C) and CTD (D) were performed as described in B. E, Mac-1 HEK293 cells were preincubated
with 5 M PTN or PTN fragments for 20 min before loading into wells coated with 100 nM PTN and postcoated with 1% PVP. Adhesion in the absence of soluble
PTN or PTN fragments was assigned a value of 100%. Data shown are means ⫾ S.E. from three separate experiments with sextuplicate measurements. Error bars
represent S. E. *, p ⱕ 0.05; ***, p ⱕ 0.001 compared with control adhesion in the absence of inhibitors. F, Mac-1 HEK293 cells were treated with 0.7 M PTN or
PTN fragments. After 30 min at 37 °C, cells were lysed, and lysates were separated by 12.5% SDS-PAGE. Western blotting was performed using the mAb specific
for the phosphorylated form of Erk1/2 (p-Erk1/2). The mAb against total Erk1/2 was used to equalize protein loading. A representative of three experiments is
shown.

sequence identity and a similar tertiary structure with PTN, is
expressed in damaged tissues and has a comparable proinflammatory profile (47). It has been reported that MK enhances
migration of inflammatory leukocytes in a number of pathological conditions induced in experimental animals (14, 48 –52).

MK receptors responsible for triggering these responses are not
known, but MK has been shown to activate both ␤1 and ␤2
integrins (53, 54). Furthermore, adhesion to immobilized MK
was shown to be mediated by ␤2 integrins, although the nature
of ␣ subunit pairing with the ␤2 subunit has not been deter-

Figure 7. Screening the peptide library spanning the sequence of PTN for ␣MI domain binding. The assembled peptide library spanning the sequence of
PTN consisting of 9-mer peptides with 3-residue offset (A) was incubated with 125I-labeled active ␣MI domain (residues Glu123–Lys315) and subjected to
autoradiography (B). The ␣MI domain binding was observed as dark spots. Spots 49 and 50 contain only the ␤-Ala spacer. The numbers in the right columns in
A show the relative binding of the ␣MI domain to peptides determined by densitometry and expressed as a percentage of the intensity of the most active
peptide, KTRTGSLKR (spot 29). Peptide energies (middle columns in A) that serve as a measure of the probability each peptide can bind the ␣MI domain were
calculated as described (29). C, the ribbon model of PTN based on Protein Data Bank code 2N6F. Side chains of Arg and Lys are shown in stick representations.
The four clusters with peptides identified as positive for the ␣MI domain binding are shown in purple.
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mined. Both PTN and MK have also been shown to induce
expression of inflammatory cytokines in peripheral blood
monocytes (47, 55). Because ligand engagement by Mac-1 is
known to initiate intracellular signaling that regulates numerous leukocyte responses, including expression of cytokines, a
receptor that mediates this effect upon PTN and MK binding is
most likely to be Mac-1. The potential role of PTN in inducing
other reactions of monocyte/macrophages that are known to be
mediated by Mac-1 merits further investigation.

Experimental procedures
Reagents
The mouse mAb 44a directed against the human ␣M integrin
subunit was purified from conditioned media of hybridoma
cells obtained from the American Type Culture Collection
(Manassas, VA) using protein A-agarose. Alexa Fluor 546-conjugated phalloidin was purchased from Life Technologies. The
mouse mAb G3A1, an IgG1 isotype control for mAb 44a, was
obtained from Cell Signaling Technology (Beverly, MA). BSA,
polyvinylpyrrolidone (PVP), EDTA, heparin, and aggrecan
were purchased from Sigma. Calcein-AM was purchased from
Molecular Probes (Eugene, OR). mAbs directed to total Erk1/2
and the phosphorylated form of Erk1/2 were from Cell Signaling Technology. Goat anti-rabbit IgG (heavy ⫹ light)-HRP conjugated antibody was from Bio-Rad. Protease and phosphatase
inhibitor mixture was from Thermo Scientific (Rockford, IL).
Expression and purification of recombinant proteins
Expression and purification of PTN were performed as
described previously (25). Briefly, human PTN ORF cloned into
the pET-15b vector was transformed into Origami B (DE3) cells
(Novagen, Madison, WI). The transformed cells were grown in
M9 medium at 37 °C until induction with 0.25 mM isopropyl
1-thio-␤-D-galactopyranoside when A600 reached 0.8. The culture was then incubated with shaking overnight at room temperature. The PTN was purified from supernatant using hepa-
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rin-affinity chromatography with a 5-ml HiTrap heparin
column (GE Healthcare). Truncated PTN fragments, PTNshort (residues Gly1–Lys114), NTD (residues Gly1–Cys57), and
CTD (residues Asn58–Lys114) were cloned into the pET-15b
vector and expressed as described above. Expression of recombinant active (residues ␣MGlu123–Lys315) and nonactive (residues ␣MGln119–Glu333) ␣MI domains as well as active ␣LI
domain (residues ␣LGly127–Tyr307; K287C,K294C) were described previously (39). Alternatively, the ␣MI domain ORF was
cloned into pHUE vector (56) as a fusion protein with ubiquitin
and transformed into BL21 (DE3) cells (Bioline). The ␣MI
domains were purified with 5-ml HisTrap HP nickel columns
(GE Healthcare). To remove the His-tagged ubiquitin, the
fusion protein was incubated with the ubiquitinase USP2 overnight at a protein-to-enzyme ratio of 30:1. The pure ␣MI
domain was separated from other impurities by size-exclusion
chromatography using a Superdex 75 column (GE Healthcare).
The ␣MI domain was biotinylated with EZ-Link Sulfo-NHSLC-Biotin (Thermo Fisher Scientific, Inc., San Jose, CA). The
efficiency of biotinylation was tested using a biotin quantitation
assay kit (Thermo Fisher Scientific, Inc.) with biotinylated
horseradish peroxidase as a standard.
Screening of peptide libraries for ␣MI domain binding
A peptide library was prepared by parallel spot synthesis on
cellulose membranes as described previously (57, 58). Purified
recombinant ␣MI domain was labeled with 125I using Iodo-Gen
(Pierce). The library spanning the sequence of PTN was synthesized as 9-mer overlapping peptides with a 3-amino acid offset.
Peptides were C-terminally attached to the cellulose via a
(␤-Ala)2 spacer and were acetylated N-terminally. The membrane with attached peptides was blocked with 1% BSA and
then incubated with 10 g/ml 125I-labeled ␣MI domain in TBS
containing 1 mM MgCl2, 0.05% Tween 20, and 1 mM dithiothreitol. After washing, the membrane was dried, and the ␣MI
domain binding was visualized by autoradiography and analyzed by densitometry.
NMR
PTN 1H-15N HSQC NMR data were collected using a Bruker
600-MHz Avance III HD spectrometer (Bruker Corp., Billerica,
MA) equipped with a Prodigy probe. The NMR samples contained 40 M PTN in PBS buffer at pH 7.5 and either 0 or 40 M
unlabeled ␣MI domain. Data were processed using NMRPipe
(59) and analyzed with NMRView (60).
Cells
HEK293 and Mac-1 HEK293 cells were described previously
(61). The cells were maintained in DMEM (Mediatech Inc.,
Manassas, VA) with 10% fetal bovine serum and antibiotics.
The IC-21 mouse macrophage cell line was obtained from
ATCC. Mouse peritoneal macrophages were isolated from
the peritoneal lavage of wild-type (C57BL/6J) and Mac-1⫺/⫺
(B6.129S4-Itgamtm1Myd/J) mice 3 days after thioglycolate injection using the EasySep Mouse selection kit (StemCell Technologies) with mAb F4/80 conjugated to FITC.
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Cell adhesion assays
Cell adhesion assays were performed according to methods
described previously (36, 61). Briefly, 96-well microtiter plates
(Immulon 4HBX, Thermo) were coated with different concentrations of PTN and PTN fragments (PTN, PTN-short, CTD,
and NTD) for 3 h at 37 °C and blocked with 1% PVP in PBS for
1 h at 37 °C. The cells were labeled with 7.5 M calcein-AM
(Thermo) for 30 min at 37 °C. The labeled cells were washed
with Hanks’ balanced salt solution containing 0.1% BSA and
resuspended in the same buffer at a concentration of 5 ⫻ 105/
ml. Aliquots (100 l) of labeled cells were added to each well
and incubated for 30 min at 37 °C. Non-adherent cells were
removed with two washes with PBS, and fluorescence was measured with a fluorescence plate reader (Perseptive Biosystems,
Framingham, MA). For inhibition experiments, labeled cells
were treated with 5 g/ml anti-Mac-1 antibodies (anti-␣M
mAb 44a and M1/70 for Mac-1 HEK293 and IC-21 macrophages, respectively) or heparin (1 g/ml) for 15 min at 22 °C
before they were added to the wells. For PTN inhibition experiments, cells were treated with either 2 or 5 M soluble PTN or
PTN fragments for 20 min at 22 °C before they were added to
the wells. To test the effect of aggrecan-bound PTN, 10 g/ml
aggrecan in PBS was used to coat 96-well microtiter plates overnight at 4 °C as described (62). Then PTN was added to aggrecan-coated wells for 3 h at 37 °C. The remaining steps were the
same as described above. The coating efficiency of aggrecan was
determined using biotinylated aggrecan.
Cell migration assays
Cell migration assays were performed under sterile conditions using Transwell inserts (Costar, Corning, NY) with a pore
size of 8 (HEK293 cells) or 5 m (macrophages) as described
(30, 38). Briefly, after coating PTN on the Transwell membrane
at 37 °C for 3 h, cells (100 l) were loaded in the upper chamber
of the Transwell system at a concentration of 3 ⫻ 106/ml. For
inhibition experiments, cells were pretreated with 20 g/ml
anti-␣M mAb 44a or 1 g/ml heparin for 20 min at 22 °C before
loading into the upper chamber of the Transwell system. The
lower chamber contained 600 l of DMEM. Migration took
place at 37 °C in a 5% CO2 humidified atmosphere for 16 h. For
detection, the HEK293 cells were labeled with calcein-AM for
30 min at 37 °C, and macrophages were labeled with FITC during isolation. Cells from the upper chamber of the Transwells
were removed by wiping with a cotton-tipped applicator.
Images of the cells on the underside of the Transwell filter were
taken with a Leica DM 4000B microscope camera (Leica, Buffalo Grove, IL).
Cell spreading assays
For cell spreading assays, glass coverslips coated with 1.5
g/ml PTN were placed in 6-well plates (Costar), and 4 ⫻ 105
cells were added to each well. After incubation at 37 °C for
different times (30 min, 1, 2, 8, and 24 h), cells were washed with
PBS, fixed with 2% paraformaldehyde for 10 min at room temperature, and then treated with 0.1% Triton X-100. For actin
staining, the cells were treated with 200 l of 165 mM phalloidin
solution for 20 min at room temperature. DAPI was added for
DNA staining. The specimens were imaged with a Leica SP5

laser-scanning confocal microscope using 63⫻/1.4 objective.
The diameters of 20 –50 cells for each time point were counted
using ImageJ software from images taken with a 20⫻/0.5 objective. The diameter was defined as the largest distance between
two opposite sides of the cell.
Biolayer interferometry
The experiments were performed using an Octet K2 instrument (ForteBio, Pall Corp.). Purified PTN was immobilized on
the amine-reactive second-generation (AR2G) biosensor using
the amine coupling kit according to the manufacturer’s protocol. Different concentrations of the active and nonactive forms
of ␣MI domain and active ␣LI domain were applied in the
mobile phase, and the association between the immobilized and
flowing proteins was detected. Experiments were performed in
20 mM HEPES, 150 mM NaCl, 1 mM MgCl2, and 0.05% (v/v)
Tween 20, pH 7.5, or in 20 mM HEPES, 150 mM NaCl, 5 mM
EDTA, and 0.05% (v/v) Tween 20, pH 7.5. The PTN-coated
surface was regenerated with 25 mM NaOH. Analyses of the
binding kinetics were performed using ForteBio Data Analysis
9.0 software. The Kd was obtained by curve fitting of the association and dissociation phases of sensorgrams using a heterogeneous ligand model. BLI experiments were also carried out
using PTN biotinylated through glutamate or aspartate side
chains with amine-PEG2-biotin (Thermo Fisher Scientific).
Biotinylated PTN at a concentration 50 g/ml was immobilized
on the streptavidin biosensor in 20 mM HEPES buffer supplemented with 150 mM NaCl, 0.1% BSA, 0.02% Tween 20, 1 mM
MgCl2, and 1 mM CaCl2 for 15 min, which generated a saturated
level of PTN on the biosensor. After immobilization, the biosensor was washed with HEPES buffer, and different concentrations of ␣MI domain were added to the immobilized PTN.
After each association– dissociation cycle, the biosensor was
regenerated using 20 mM NaOH.
Western blotting
HEK293 cells and Mac-1 HEK293 cells were added to the
wells of 6-well culture plates at 2 ⫻ 106/well and cultured for 2 h
in DMEM/F-12 ⫹ 10% FBS. Adherent cells were treated with
PTN and PTN fragments (0.7 M). After 30 min at 37 °C in a
humidified 5% CO2 atmosphere, cells were washed with icecold PBS containing a protease and phosphatase inhibitor mixture. Next, 200 l of the lysis buffer (50 mM Tris-HCl, pH 7.4,
1% Triton X-100, 150 mM NaCl, 1 mM EDTA, and protease and
phosphatase inhibitor mixture) was added to each well, and
cells were incubated on ice for 1 h. Protein concentration in the
lysates was quantified by a BCA assay (Thermo Scientific), and
equal amounts of protein (20 g) were loaded onto 12.5% SDSpolyacrylamide gels. After the transfer of proteins onto nitrocellulose membranes, the membranes were blocked with skim
milk and incubated with anti-Erk1/2 and anti-phospho-Erk1/2
(Tyr202 and Tyr204) rabbit mAbs. The mAb binding was
detected using HRP-conjugated goat anti-rabbit antibodies and
chemiluminescence (Thermo Scientific).
Statistical analysis
All data are presented as the mean ⫾ S.E. The statistical
differences were determined using one-way analysis of variance
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using SigmaPlot 11.0 software (Systat Software, San Jose, CA).
For multiple comparisons, the Bonferroni correction method
was used. Differences were considered significant if the p value
was less than 0.05.
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